Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the complement ...
The independent technology information source for electronics engineers, programmers and developers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback